ALGN Align Technology (ALGN) Insider Trading, Ownership & Congress Trades
Medical Devices · Orthopedic, prosthetic & surgical appliances & supplies · CIK 0001097149
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
301
13F, latest reported quarter
Conversions, 180 days
10
Codes C/M, not in net · $0 priced
What the filings say about ALGN
Congress, 1 year
No trades
Last one: sale, 2025-09-11
Align Technology insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for ALIGN TECHNOLOGY INC in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 2 earlier Form 4 trades (code P or S) here by this insider (1 buy, 1 sale), the last on Feb 8, 2023.
- The trade is 96.7% of the 8,237 shares held after it.
- No other insider sold within 30 days.
- 301 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, CHIEF FINANCIAL OFFICER Morici John sold about $1.5M of ALGN on Feb 18, 2026, the largest insider sale at the company since 2024; 301 funds added in the latest 13F quarter.Context
- 23 earlier Form 4 trades (code P or S) here by this insider (5 buys, 18 sales), the last on Nov 9, 2023.
- +46.5% median (+26.0% mean) 90-day return after 5 previous buys.
- The trade is 4.1% of the 184,945 shares held after it.
- 1 other insider bought within 30 days.
- 301 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: PRESIDENT AND CEO HOGAN JOSEPH M bought about $996.2K of ALGN on Aug 1, 2025; 1 other insider bought within 30 days and 301 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Aug 4, 2021.
- The trade is 0.6% of the 7,110 shares held after it.
- 1 other insider bought within 30 days.
- 301 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, CHIEF LEGAL & REGULATORY Coletti Julie Ann bought about $4.6K of ALGN on Jul 31, 2025; 1 other insider bought within 30 days and 301 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (1 buy, 2 sales), the last on May 13, 2022.
- The trade is 23.0% of the 28,247 shares held after it.
- No other insider bought within 30 days.
- 301 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director LARKIN C RAYMOND JR bought about $1.5M of ALGN on Aug 15, 2024, the largest insider purchase at the company since 2023; 301 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Feb 27, 2024.
- The trade is 0.6% of the 131,994 shares held after it.
- 1 other insider sold within 30 days.
- 301 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director LACOB JOSEPH sold about $243.8K of ALGN on Feb 29, 2024; 1 other insider sold within 30 days and 301 funds added in the latest 13F quarter.65 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
301 funds bought in last quarter
more than 89% of Medical Devices
Revenue
+0.9% year over year
below 76% of Medical Devices
Margin
10.2% net margin
more than 82% of Medical Devices
Buybacks
$98.1M repurchased, FY to 2026-06-30
more than 59% of Medical Devices
Short interest
6.3% of the float short (float per yahoo 2026-10-26) · 4.3 days to cover · settled 2026-09-30
more than 69% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch ALGN
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+11.7%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ALGN: institutional holders (13F)
13F holdings, latest reported quarter
4,419,366 sh
$745.4M
4,401,313 sh
$742.3M
4,060,032 sh
$684.8M
4,045,561 sh
$682.3M
3,422,385 sh
$577.2M
Congress trades in ALGN
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2025-09-11 · disclosed 41 days later
$1,001 - $15,000
Bought 2025-08-04 · disclosed 39 days later
$1,001 - $15,000
Sold 2025-04-08 · disclosed 30 days later
$1,001 - $15,000
Sold 2025-02-26 · disclosed 8 days later
$1,001 - $15,000
Bought 2025-02-25 · disclosed 30 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ALGN planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
ALGN mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
DAVENPORT EQUITY OPPORTUNITIES FUND
$30.9M position · as of 2026-06-30
3.9%
Virtus KAR Mid-Cap ETF
$1.6M position · as of 2026-07-31
3.4%
Simplify Health Care ETF
$11.3M position · as of 2026-06-30
3.1%
Virtus KAR Health Sciences Fund
$2.6M position · as of 2026-06-30
2.9%
Virtus KAR Mid-Cap Core Fund
$46.8M position · as of 2026-06-30
2.7%
The Disciplined Growth Investors Equity Fund
$4.1M position · as of 2026-07-31
2.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Joseph Hogan
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$19.2M
$3.9M
$4.3M
-71%
+17%
2024
$27.3M
$5.2M
$4.8M
-61%
+10%
2023
$29.0M
$29.5M
$4.4M
-49%
+0%
2022
$18.7M
-$61.3M
$3.4M
-61%
-7%
2021
$21.6M
$76.2M
$4.3M
+23%
+19%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 301 funds added last quarter. Each figure is a federal filing, dated the day it went public.
ALGN financials
Revenue growth
+0.9%
XBRL, annual
Net margin
10.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$4.1B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM ALGN
| FY Dec 2025 | $4.0B |
| FY Dec 2024 | $4.0B |
| FY Dec 2023 | $3.9B |
| FY Dec 2022 | $3.7B |
| FY Dec 2021 | $4.0B |
| Jun 2026 | $1.1B |
| Mar 2026 | $1.0B |
| Dec 2025 | $1.0B |
| Sep 2025 | $995.7M |
| Jun 2025 | $1.0B |
| Mar 2025 | $979.3M |
| Dec 2024 | $995.2M |
| Sep 2024 | $977.9M |
At each fiscal year end
Single quarter
Net margin, TTM
+10.0%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM ALGN
| FY Dec 2025 | +10.2% |
| FY Dec 2024 | +10.5% |
| FY Dec 2023 | +11.5% |
| FY Dec 2022 | +9.7% |
| FY Dec 2021 | +19.5% |
| Jun 2026 | +10.3% |
| Mar 2026 | +10.8% |
| Dec 2025 | +12.9% |
| Sep 2025 | +5.7% |
| Jun 2025 | +12.3% |
| Mar 2025 | +9.5% |
| Dec 2024 | +10.4% |
| Sep 2024 | +11.9% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$633.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM ALGN
| FY Dec 2025 | $490.8M |
| FY Dec 2024 | $622.7M |
| FY Dec 2023 | $608.1M |
| FY Dec 2022 | $276.8M |
| FY Dec 2021 | $771.4M |
| Jun 2026 | $157.1M |
| Mar 2026 | $120.3M |
| Dec 2025 | $187.3M |
| Sep 2025 | $169.0M |
| Jun 2025 | $107.2M |
| Mar 2025 | $27.4M |
| Dec 2024 | $263.1M |
| Sep 2024 | $233.9M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity ALGN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt ALGN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+10.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity ALGN
| FY Dec 2025 | +10.4% |
| FY Dec 2024 | +11.3% |
| FY Dec 2023 | +12.3% |
| FY Dec 2022 | +10.0% |
| FY Dec 2021 | +22.5% |
| Jun 2026 | +10.1% |
| Mar 2026 | +10.8% |
| Dec 2025 | +10.4% |
| Sep 2025 | +9.6% |
| Jun 2025 | +11.4% |
| Mar 2025 | +10.8% |
| Dec 2024 | +11.3% |
| Sep 2024 | +11.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+6.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets ALGN
| FY Dec 2025 | +6.6% |
| FY Dec 2024 | +6.8% |
| FY Dec 2023 | +7.4% |
| FY Dec 2022 | +6.1% |
| FY Dec 2021 | +14.3% |
| Jun 2026 | +6.5% |
| Mar 2026 | +6.9% |
| Dec 2025 | +6.6% |
| Sep 2025 | +6.0% |
| Jun 2025 | +7.1% |
| Mar 2025 | +6.7% |
| Dec 2024 | +6.8% |
| Sep 2024 | +7.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
no debt line filed
Return on invested capital ALGN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+12.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed ALGN
| FY Dec 2025 | +12.9% |
| FY Dec 2024 | +14.8% |
| FY Dec 2023 | +16.0% |
| FY Dec 2022 | +16.0% |
| FY Dec 2021 | +26.0% |
| Jun 2026 | +12.5% |
| Mar 2026 | +13.1% |
| Dec 2025 | +12.9% |
| Sep 2025 | +12.5% |
| Jun 2025 | +14.4% |
| Mar 2025 | +14.2% |
| Dec 2024 | +14.8% |
| Sep 2024 | +14.9% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
26.47x
close 2026-10-27 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing ALGN
| FY Dec 2025 | 27.64x |
| FY Dec 2024 | 37.17x |
| FY Dec 2023 | 47.16x |
| FY Dec 2022 | 45.75x |
| FY Dec 2021 | 67.75x |
| Jun 2026 | 29.38x |
| Mar 2026 | 28.81x |
| Dec 2025 | 27.64x |
| Sep 2025 | 24.27x |
| Jun 2025 | 31.93x |
| Mar 2025 | 28.94x |
| Dec 2024 | 37.17x |
| Sep 2024 | 43.47x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value ALGN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+5.9%
TTM free cash flow over market value at close 2026-10-27
FCF yield ALGN
| FY Dec 2025 | +4.4% |
| FY Dec 2024 | +4.0% |
| FY Dec 2023 | +2.9% |
| FY Dec 2022 | +1.7% |
| FY Dec 2021 | +1.5% |
| Jun 2026 | +5.2% |
| Mar 2026 | +4.8% |
| Dec 2025 | +4.4% |
| Sep 2025 | +6.2% |
| Jun 2025 | +4.6% |
| Mar 2025 | +5.4% |
| Dec 2024 | +4.0% |
| Sep 2024 | +2.0% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing EPS growth -3%, PEG needs growth
PEG, trailing ALGN
| FY Dec 2025 | 38.76x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 1.81x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | 3.44x |
| Dec 2025 | 38.76x |
| Sep 2025 | n/a |
| Jun 2025 | 37.55x |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | 1.82x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $4.0B | $4.0B | $3.9B | $3.7B |
| Gross profit | $2.7B | $2.8B | $2.7B | $2.6B |
| Operating income | $545.8M | $607.6M | $643.3M | $642.6M |
| Net income | $410.0M | $421.0M | $445.0M | $362.0M |
| EPS (diluted) | 5.65 | 5.62 | 5.81 | 4.61 |
| Operating cash flow | $593.2M | $738.2M | $785.8M | $568.7M |
| Cash | $1.1B | $1.0B | $937.4M | $942.0M |
| Buybacks | $465.9M | $352.9M | $592.4M | $435.0M |
SEC XBRL, fiscal years, as known on 2026-10-28
ALGN Stock Sonar score 4/7 axes
Find similar shapesCompareALGN ranks highest on institutional and government (89th percentile) and profitability (82nd), and lowest on growth (25th), among Medical Devices peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ALGN filings, in plain words
Have members of Congress traded ALGN?
Yes, but not in the year to 2026-10-28; the latest on record is a sale by Lisa McClain dated 2025-09-11.
Read the full summary
Members of Congress have disclosed trades in ALGN, none in the last year; the latest on record is a sale by Lisa McClain dated 2025-09-11. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
